Share on StockTwits

LeMaitre Vascular (NASDAQ:LMAT) Director Cornelia W. Lemaitre sold 4,700 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, June 25th. The shares were sold at an average price of $8.32, for a total transaction of $39,104.00. Following the transaction, the director now directly owns 174,581 shares of the company’s stock, valued at approximately $1,452,514. The transaction was disclosed in a filing with the SEC, which is available at this link.

A number of research firms have recently commented on LMAT. Analysts at Stifel Nicolaus initiated coverage on shares of LeMaitre Vascular in a research note on Tuesday, June 24th. They set a “buy” rating and a $11.00 price target on the stock. Finally, analysts at Brean Capital initiated coverage on shares of LeMaitre Vascular in a research note on Monday, May 19th. They set a “buy” rating and a $11.00 price target on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. LeMaitre Vascular currently has an average rating of “Buy” and an average price target of $10.47.

Shares of LeMaitre Vascular (NASDAQ:LMAT) opened at 8.27 on Tuesday. LeMaitre Vascular has a 1-year low of $6.38 and a 1-year high of $8.96. The stock’s 50-day moving average is $7.64 and its 200-day moving average is $7.91. The company has a market cap of $129.3 million and a price-to-earnings ratio of 60.36.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.01 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.02 by $0.01. Analysts expect that LeMaitre Vascular will post $0.23 EPS for the current fiscal year.

LeMaitre Vascular, Inc (NASDAQ:LMAT) is a global provider of medical devices and implants for the treatment of peripheral vascular disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.